IBER.U (Ibere Pharmaceuticals) Cash per Share : $0.00 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Ibere Pharmaceuticals's Cash per Share for the quarter that ended in Sep. 2022 was $0.00.

Ibere Pharmaceuticals Cash per Share Historical Data

The historical data trend for Ibere Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Cash per Share Chart

Ibere Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Cash per Share

Ibere Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash per Share	Get a 7-Day Free Trial			-	-	-	-	-

Ibere Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Ibere Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.458	/	0.00
	=	N/A

Ibere Pharmaceuticals's Cash per Share for the quarter that ended in Sep. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.004	/	0.00
	=	N/A

Ibere Pharmaceuticals (NYSE:IBER.U) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Ibere Pharmaceuticals Cash per Share Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibere Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103

Website

https://www.iberepharma.com

Ibere Pharmaceuticals is a blank check company.

Executives

Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie	director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes	director, 10 percent owner, officer: Chief Operating Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray	director, 10 percent owner, officer: Chief Financial Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc	10 percent owner	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021